Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simulations PlusSLP 82 3-Year EPS without NRI Growth Rate is -18.60% as of May. 2026. GuruFocus rates SLP with a GF Score™ of 82/100 and a GF Value™ of $35.20 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Simulations Plus ranks worse than 83.2% on this metric.
During the past 12 months, Simulations Plus's average EPS without NRI Growth Rate was -34.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -18.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -4.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Simulations Plus was 78.70% per year. The lowest was -39.10% per year. And the median was 15.70% per year.
Simulations Plus (NAS:SLP) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Simulations Plus 3-Year EPS without NRI Growth Rate Related Terms
SLP vs CTEV, TBRG, CARL: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Simulations Plus's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Simulations Plus's 3-Year EPS without NRI Growth Rate falls into.
Simulations Plus 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -18.60% mean?
Simulations Plus (SLP) has a 3-Year EPS without NRI Growth Rate of -18.60% as of May. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #421 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 83.2%.
Is Simulations Plus' 3-Year EPS without NRI Growth Rate too high?
Simulations Plus' current 3-Year EPS without NRI Growth Rate is -18.60%. Based on the distribution chart, Simulations Plus ranks #421 out of 506 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Simulations Plus has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' 3-Year EPS without NRI Growth Rate compare to CTEV and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #421 out of 506 companies for 3-Year EPS without NRI Growth Rate. This places Simulations Plus in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current 3-Year EPS without NRI Growth Rate is -18.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.20, compared to a current price of $18.39 — trading 47.8% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -18.60%. Simulations Plus' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Simulations Plus (SLP), the current 3-Year EPS without NRI Growth Rate is -18.60% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.39 is trading 47.8% below its estimated GF Value™ of $35.20.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
3-Year EPS without NRI Growth Rate: -18.60%
GF Value™: $35.20 vs. price of $18.39 (47.8% below fair value)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
82GF Score
Get the complete analysis for SLP
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
